CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical ...

Main products in the clinical stage include: Batoclimab (HBM9161) is the first anti-FcRn monoclonal antibody completed Phase I to pivotal trials in China. As a novel, fully human anti-FcRn ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an NEW YORK, March 18, 2025 (GLOBE ...